SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending following positive Phase 2 trial data for its skin drug, sonelokimab, leading to significant price movement and high volatility. The community is actively discussing the implications of the results, potential buyout scenarios, and the company's overall valuation with some users expressing concerns over a potential offering. Bullish sentiment seems high, but bears warn against high placebo response in study 2.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced private placement, with the community actively discussing whether the stock can sustain its momentum. Some traders believe the financing deal could be dilutive, while others are optimistic about a potential short squeeze given the tight float. Overall, traders are closely monitoring JFB for potential continuation or pullback.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following positive Phase 3 trial results for its oral Wegovy pill, showing similar weight loss efficacy to the injectable version; the community is discussing the potential for increased demand and market dominance if approved. However, some analysts point to downgrades citing slower growth, competition, and margin pressure, creating a debate around the company's future prospects. Investors are weighing the potential impact of these factors against Novo Nordisk's strong position in the growing GLP-1 market.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a community-driven crypto embracing cannabis culture and freedom. Community members highlight Weedcoin as more than a token; it's a movement for culture, connection, and growth, built on positivity and good vibes. The crypto is seen as a way to connect the cannabis industry with blockchain technology.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to a massive volume spike and significant price volatility, with community members weighing entry points. Discussions revolve around the potential impact of a competitor's ($MLTX) data and speculation about future catalysts. Bullish sentiment is fueled by analyst ratings and price target increases.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V

Merus is trending following news of Genmab's acquisition of the company for $8 billion, or $97 per share, sparking excitement among biotech investors. The community is buzzing about the buyout price and potential implications for other companies in the sector. Some investors are expressing regret for selling their shares earlier, while others are drawing comparisons to similar acquisitions.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as investors discuss the implications of their recent AI hosting deal with Fluidstack, backed by Google, and a large convertible note offering. Community members are weighing the potential for significant growth in the AI data center space against concerns about dilution, while highlighting the company's measures to protect shareholders. The discussion also includes speculation about future deals and the potential for the stock to benefit from rising Bitcoin prices.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders weigh the potential impacts of a looming government shutdown and speculate on its effects on the market, particularly regarding the release of upcoming jobs data. Community discussions revolve around potential market reactions, with some anticipating a bullish outcome if a shutdown is averted, while others are bracing for volatility and a possible downturn, especially given concerns about high stock valuations and AI-driven market dynamics.

Advisorshares Trust - AdvisorShares MSOS 2x Daily ETF

AdvisorShares MSOS Daily Leveraged ETF

MSOX is trending as investors discuss potential catalysts for cannabis stocks, including possible rescheduling and Trump's stance on the industry. Community members are weighing the risks and potential rewards, with some anticipating significant gains while others remain cautious due to the sector's volatility. Bullish sentiment seems to be building amid speculation of upcoming news and a possible short squeeze.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals is trending due to the upcoming presentation of topline results from its Phase 2b study of Zelicapavir for RSV in high-risk adults, sparking considerable interest and anticipation within the investment community. Community members are actively discussing potential outcomes, speculating on significant price movements based on positive results, and highlighting unusual options activity that suggests bullish sentiment. The focus remains on the potential of the drug and its impact on the company's valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cheniere Partners Q2 Earnings Miss Estimates, Revenues Beat

CQP's Q2 profit misses estimates as LNG volumes fall, but revenues rise to $2.5B, topping forecasts.

Top Analyst Reports for Alphabet, Bank of America & Roche

Delek Logistics Set to Report Q1 Earnings: What's in the Cards?

Cheniere Energy: Stifel lowers PT, downgrades to 'Sell' on limited upside

Investing.com-- Stifel analysts downgraded their rating for  Cheniere Energy Partners  LP (NYSE:CQP) (CQP) and reduced the price target citing limited upside and overvaluation after a recent rally.

Cheniere Partners Reports Fourth Quarter and Full Year 2024 Results and Introduces Full Year 2025 Distribution Guidance

Cheniere Energy Partners, L.P. (Cheniere Partners) (NYSE: CQP) today announced its financial results for fourth quarter and full year 2024. HIGHLIGHTS During the three and twelve months ended...

Cheniere Partners Declares Quarterly Distributions

Cheniere Energy Partners, L.P. (Cheniere Partners) (NYSE: CQP) today declared (i) a cash distribution of $0.820 per common unit to unitholders of record as of February 10, 2025, comprised of a base...

Cheniere Announces Timing of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

Cheniere Energy, Inc. (Cheniere) (NYSE: LNG) announced today that it plans to issue its earnings release with respect to fourth quarter and full year 2024 financial results on Thursday, February 20...

Cheniere Announces Publication of Updated Peer-Reviewed LNG Life Cycle Assessment

Cheniere Energy, Inc. (Cheniere or the Company) (NYSE: LNG) today announced the publication of an updated life cycle assessment (LCA) study for greenhouse gas (GHG) emissions intensities of the...

Cheniere Partners Reports Third Quarter 2024 Results and Reconfirms Full Year 2024 Distribution Guidance

Cheniere Energy Partners, L.P. (Cheniere Partners) (NYSE: CQP) today announced its financial results for third quarter 2024. HIGHLIGHTS During the three and nine months ended September 30, 2024...

Cheniere Establishes Methane Emissions Intensity Target for its Liquefaction Assets

Cheniere Energy, Inc. (Cheniere or the Company) (NYSE: LNG) today announced it has set a voluntary, measurement-informed Scope 1 annual methane intensity target for its liquefaction facilities. The...

Cheniere Energy Partners LP engages in the operations of liquefied natural gas. It provides LNG to integrated energy companies, utilities, and energy trading companies around the world. The company was founded in 2006 and is headquartered in Houston, TX.

Current Price	$54.03
Prev Close	$53.79
Open	$53.53
Dividend Yield	6.52%
50-Day Moving Average	$54.25
Beta	0.67
Avg. Volume	94,087.48
PE Ratio	13.06

52-Week High	$68.31
52-Week Low	$47.41
Market Capitalization	$26.15B
EPS (Annual)	$4.28
Price to Book	11.90
Revenue Per Employee	$5.08M
Enterprise Value/EBITDA	N/A

CQP
Cheniere Energy Partners LP.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CQP News

CQP Cheniere Energy Partners LP.